[HTML][HTML] HR+/HER2− de novo metastatic breast cancer: a true peculiar entity?
R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - Drugs in …, 2023 - ncbi.nlm.nih.gov
De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
[PDF][PDF] HR+/HER2–de novo metastatic breast cancer: a true pe-culiar entity
R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - Drugs …, 2023 - researchgate.net
De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
[PDF][PDF] HR+/HER2–de novo metastatic breast cancer: a true pe-culiar entity
R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - Drugs …, 2023 - drugsincontext.com
De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
HR+/HER2-de novo metastatic breast cancer: a true peculiar entity?
R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - DRUGS, 2023 - iris.hunimed.eu
: De novo metastatic breast cancer (dnMBC) accounts for~ 6-10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
HR+/HER2-de novo metastatic breast cancer: a true peculiar entity?
R Torrisi, F Jacobs, C Miggiano… - Drugs in …, 2023 - pubmed.ncbi.nlm.nih.gov
De novo metastatic breast cancer (dnMBC) accounts for~ 6-10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?
R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - Drugs in …, 2023 - europepmc.org
De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
[PDF][PDF] HR+/HER2–de novo metastatic breast cancer: a true pe-culiar entity
R Torrisi, F Jacobs, C Miggiano… - Drugs …, 2023 - pdfs.semanticscholar.org
De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
HR+/HER2- de novo metastatic breast cancer: a true peculiar entity?
R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - Drugs in …, 2023 - europepmc.org
De novo metastatic breast cancer (dnMBC) accounts for~ 6-10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
[PDF][PDF] HR+/HER2–de novo metastatic breast cancer: a true pe-culiar entity
R Torrisi, F Jacobs, C Miggiano, R De Sanctis… - Drugs …, 2023 - researchgate.net
De novo metastatic breast cancer (dnMBC) accounts for~ 6–10% of all breast cancers and
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …
for~ 30% of MBC with increasing incidence over time. Hormone receptor-positive/human …